Risk of dementia and Parkinson's disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: A nationwide population-based cohort study.

Risk of dementia and Parkinson's disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: A nationwide population-based cohort study.

Recent studies reported conflicting results on the association of androgen deprivation therapy (ADT) with dementia and Parkinson's disease in patients with prostate cancer (Pca). Therefore, this study aimed to investigate whether use of gonadotropin-releasing hormone agonist (GnRHa) increases t...

Full description

Bibliographic Details
Main Authors:	Myungsun Shim, Woo Jin Bang, Cheol Young Oh, Yong Seong Lee, Seong Soo Jeon, Hanjong Ahn, Young-Su Ju, Jin Seon Cho
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2020-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0244660

Similar Items

Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide
by: Myungsun Shim, et al.
Published: (2019-07-01)

Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control study
by: Myong Kim, et al.
Published: (2018-03-01)

Supposed pituitary-production of human chorionic Gonadotropin induced by androgen deprivation therapy
by: Koji Yoshimura, et al.

Response to the gonadotropin releasing hormone agonist leuprolide in immature female sheep androgenized in utero
by: SERGIO E RECABARREN, et al.
Published: (2005-01-01)

Long-term outcomes after gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty.
by: Young Suk Shim, et al.
Published: (2020-01-01)

Phase I/IIa trial of androgen deprivation therapy, external beam radiotherapy, and stereotactic body radiotherapy boost for high-risk prostate cancer (ADEBAR)
by: Yeon Joo Kim, et al.
Published: (2020-10-01)

Androgen-deprivation therapy and the risk of newly developed fractures in patients with prostate cancer: a nationwide cohort study in Korea
by: Do Kyung Kim, et al.
Published: (2021-05-01)

Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population‐based propensity score matching study
by: Bum Sik Tae, et al.
Published: (2019-08-01)

Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer
by: Jui-Ming Liu, et al.
Published: (2021-07-01)

Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer
by: Wook Nam, et al.
Published: (2018-01-01)

Effect of desmopressin lyophilisate (MELT) plus anticholinergics combination on functional bladder capacity and therapeutic outcome as the first-line treatment for primary monosymptomatic nocturnal enuresis: A randomized clinical trial
by: Myungsun Shim, et al.
Published: (2021-05-01)

Thyroid Dysfunction Associated with Administration of the Long-Acting Gonadotropin-Releasing Hormone Agonist
by: Eun Jin Han, et al.
Published: (2013-09-01)

Gonadotropin releasing hormone agonists: Expanding vistas
by: Navneet Magon
Published: (2011-01-01)

A Case of Thromboembolism After Injection of Gonadotropin-releasing Hormone Agonist
by: Feng Zhou, et al.
Published: (2016-01-01)

Conformational dynamics of androgen receptors bound to agonists and antagonists
by: Hyo Jin Gim, et al.
Published: (2021-08-01)

Prostate cancer incidence under androgen deprivation: A nationwide cohort study in trans women receiving hormone treatment
by: I. de Nie, et al.
Published: (2020-07-01)

Gonadotropin-releasing hormone agonist-induced pituitary apoplexy
by: Fergus Keane, et al.
Published: (2016-06-01)

Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study protocol for a randomized controlled, pilot trial
by: Yeon Joo Kim, et al.
Published: (2018-04-01)

Treatment outcomes of gonadotropin-releasing hormone agonist in obese girls with central precocious puberty
by: Hye Ryun Kim, et al.
Published: (2017-12-01)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
by: Shtutman Michael, et al.
Published: (2010-04-01)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
by: Shimajiri Shohei, et al.
Published: (2011-05-01)

Androgen deprivation therapy and the risk of subsequent keratitis
by: Dai-Wei Liu, et al.
Published: (2021-01-01)

Lacrimal sac adenocarcinoma managed with androgen deprivation
by: David H. Abramson, et al.
Published: (2020-09-01)

A cost-outcome analysis of androgen deprivation therapy and androgen deprivation therapy combine radiotherapy for locally advanced prostate cancer
by: Wei-Na Wang, et al.
Published: (2011)

Changing pattern of gonadotropins in a patient with an adrenal-androgen secreting tumor
by: Jose Antonio Miguel Marcondes, et al.
Published: (2011-01-01)

Short-term efficacy of 1-month and 3-month gonadotropin-releasing hormone agonist depots in girls with central precocious puberty
by: Min Jin Jeon, et al.
Published: (2021-09-01)

Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone agonist with or without growth hormone
by: Mo Kyung Jung, et al.
Published: (2014-12-01)

Androgen deprivation-induced senescence promotes outgrowth of androgen-refractory prostate cancer cells.
by: Dominick G A Burton, et al.
Published: (2013-01-01)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
by: Justin H. Hwang, et al.
Published: (2019-11-01)

Comparison of the clinical outcome of frozen-thawed embryo transfer with and without pretreatment with a gonadotropin-releasing hormone agonist
by: Jieun Kang, et al.
Published: (2018-07-01)

Prevalence of idiopathic scoliosis in girls with central precocious puberty: effect of a gonadotropin-releasing hormone agonist
by: Lindsey Yoojin Chung, et al.
Published: (2020-06-01)

Androgen deprivation modulates the inflammatory response induced by irradiation
by: Lin Paul-Yang, et al.
Published: (2009-03-01)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
by: Giovanni Corona, et al.
Published: (2021-07-01)

Androgen-regulated gonadotropin secretion in anterior pituitary cells from male rats
by: CHEN, XING-LANG, et al.
Published: (1993)

Gonadotropin-releasing hormone agonist ovulation trigger—beyond OHSS prevention
by: Juan Carlos Castillo, et al.
Published: (2020-04-01)

Patterns of dementia treatment in older adults with Parkinson’s disease using nationwide medical claims data
by: Kim, H.-J, et al.
Published: (2022)

Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty.
by: Hae Sang Lee, et al.
Published: (2018-01-01)

Age of menarche and near adult height after long-term gonadotropin-releasing hormone agonist treatment in girls with central precocious puberty
by: Joon-Woo Baek, et al.
Published: (2014-03-01)

Changes in Beck Depression Inventory scores in prostate cancer patients undergoing androgen deprivation therapy or prostatectomy.
by: Dongseong Shin, et al.
Published: (2020-01-01)

Clinical application of gonadotropin-releasing hormone analogs in children and adolescents
by: Ho-Seong Kim
Published: (2010-03-01)